BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31112063)

  • 1. Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
    McCann J; Ellis M; McGee SL; Aston-Mourney K
    Islets; 2019; 11(5):112-118. PubMed ID: 31112063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat.
    Khan S; Jena GB
    Chem Biol Interact; 2014 Apr; 213():1-12. PubMed ID: 24530320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children.
    Lundh M; Christensen DP; Damgaard Nielsen M; Richardson SJ; Dahllöf MS; Skovgaard T; Berthelsen J; Dinarello CA; Stevenazzi A; Mascagni P; Grunnet LG; Morgan NG; Mandrup-Poulsen T
    Diabetologia; 2012 Sep; 55(9):2421-31. PubMed ID: 22772764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.
    Chou DH; Holson EB; Wagner FF; Tang AJ; Maglathlin RL; Lewis TA; Schreiber SL; Wagner BK
    Chem Biol; 2012 Jun; 19(6):669-73. PubMed ID: 22726680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
    Luckhurst CA; Aziz O; Beaumont V; Bürli RW; Breccia P; Maillard MC; Haughan AF; Lamers M; Leonard P; Matthews KL; Raphy G; Stott AJ; Munoz-Sanjuan I; Thomas B; Wall M; Wishart G; Yates D; Dominguez C
    Bioorg Med Chem Lett; 2019 Jan; 29(1):83-88. PubMed ID: 30463802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MC1568 improves insulin secretion in islets from type 2 diabetes patients and rescues β-cell dysfunction caused by Hdac7 upregulation.
    Daneshpajooh M; Eliasson L; Bacos K; Ling C
    Acta Diabetol; 2018 Dec; 55(12):1231-1235. PubMed ID: 30088095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
    Kee HJ; Kook H
    J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9.
    Lenoir O; Flosseau K; Ma FX; Blondeau B; Mai A; Bassel-Duby R; Ravassard P; Olson EN; Haumaitre C; Scharfmann R
    Diabetes; 2011 Nov; 60(11):2861-71. PubMed ID: 21953612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors.
    Liu L; Dong L; Bourguet E; Fairlie DP
    Curr Med Chem; 2021; 28(42):8628-8672. PubMed ID: 34212828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Converse role of class I and class IIa HDACs in the progression of atrial fibrillation.
    Zhang D; Hu X; Li J; Hoogstra-Berends F; Zhuang Q; Esteban MA; de Groot N; Henning RH; Brundel BJJM
    J Mol Cell Cardiol; 2018 Dec; 125():39-49. PubMed ID: 30321539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors.
    Galán M; Varona S; Orriols M; Rodríguez JA; Aguiló S; Dilmé J; Camacho M; Martínez-González J; Rodriguez C
    Dis Model Mech; 2016 May; 9(5):541-52. PubMed ID: 26989193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [
    Laws MT; Bonomi RE; Kamal S; Gelovani DJ; Llaniguez J; Potukutchi S; Lu X; Mangner T; Gelovani JG
    Sci Rep; 2019 Mar; 9(1):3595. PubMed ID: 30837601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes.
    Dirice E; Ng RWS; Martinez R; Hu J; Wagner FF; Holson EB; Wagner BK; Kulkarni RN
    J Biol Chem; 2017 Oct; 292(43):17598-17608. PubMed ID: 28860191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver-Specific Knockdown of Class IIa HDACs Has Limited Efficacy on Glucose Metabolism but Entails Severe Organ Side Effects in Mice.
    Ziegler N; Raichur S; Brunner B; Hemmann U; Stolte M; Schwahn U; Prochnow HP; Metz-Weidmann C; Tennagels N; Margerie D; Wohlfart P; Bielohuby M
    Front Endocrinol (Lausanne); 2020; 11():598. PubMed ID: 32982982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
    Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
    Cells; 2021 May; 10(6):. PubMed ID: 34071497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
    Lemon DD; Horn TR; Cavasin MA; Jeong MY; Haubold KW; Long CS; Irwin DC; McCune SA; Chung E; Leinwand LA; McKinsey TA
    J Mol Cell Cardiol; 2011 Jul; 51(1):41-50. PubMed ID: 21539845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
    Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues.
    Kumar KK; Aburawi EH; Ljubisavljevic M; Leow MKS; Feng X; Ansari SA; Emerald BS
    Clin Epigenetics; 2024 Jun; 16(1):78. PubMed ID: 38862980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.